Use of Available Dosage Forms of Cephalexin in Clinical Comparison with Phenoxymethyl Penicillin and Benzathine Penicillin in the Treatment of Streptococcal Pharyngitis in Children

JOHN M. MATSEN,¹ ORDEAN TORSTENSON,² STUART E. SIEGEL,³ AND HADASSAH BACANER

Departments of Laboratory Medicine and Pathology, Pediatrics, and Microbiology, University of Minnesota
School of Medicine, Minneapolis, Minnesota 55455

Received for publication 18 April 1974

The effectiveness of cephalexin, an oral cephalosporin using a dosage equivalent to available capsular dosage forms, was studied in relation to the effectiveness of phenoxymethyl penicillin and benzathine penicillin in the treatment of 128 patients with beta-hemolytic streptococcal pharyngitis, all but six of whom had group A streptococci isolated from throat cultures. Approximately one-half, 66 patients, received cephalexin for 10 days; 34 patients received phenoxymethyl penicillin for 10 days; and 28 patients had a single injection of benzathine penicillin. There were four treatment failures determined bacteriologically post-therapy, two in the cephalexin treatment group and one each in the oral penicillin and intramuscular penicillin groups. Similar cure rates of 96.7, 97.1, and 96.4% were computed for the respective treatment regimens. Whereas intramuscular benzathine penicillin remains the regimen of choice in most instances, cephalexin appeared to be as effective as oral penicillin in the elimination of group A streptococci from the pharynx when oral treatment was desired for streptococcal pharyngitis.

Cephalexin, an orally absorbed cephalosporin, is a broad-spectrum antimicrobial agent giving satisfactory blood levels after oral administration, and has been demonstrated to be very active in vitro against beta-hemolytic streptococci (11, 12, 15, 19). It supplants an earlier developed member of the cephalosporin family, cephaloglycin, which was demonstrated to be clinically effective but was associated with low serum levels and with an unacceptably high incidence of side effects (9, 10).

The drug of choice in the treatment of beta-hemolytic streptococcal pharyngitis has been intramuscular benzathine penicillin and, to a lesser degree, the various oral penicillins and erythromycin. However, penicillin in any form is contraindicated in the treatment of patients with penicillin allergy. Erythromycin is a well-established alternative to penicillin in this circumstance (16). A similarly effective and versatile agent might merit consideration by physicians to augment his or her options in the treatment of streptococcal disease when an alternative to penicillin is necessary.

The purpose of this study was the comparison of the clinical efficacy of the orally administered cephalosporin, cephalexin, in doses consistent with available capsular dose forms, with an oral penicillin, phenoxymethyl penicillin, and with the standard intramuscular form of penicillin, benzathine penicillin.

MATERIALS AND METHODS

Patient population. Patients in this study presented with symptoms suggestive of beta-hemolytic infection at the pediatric outpatient departments of St. Paul Ramsey Hospital, St. Paul, and Hennepin County General Hospital, Minneapolis, Minn. A presumptive diagnosis of streptococcal pharyngitis was made on the basis of clinical findings and, in the case of those on whom treatment was deferred, culture evidence of group A Streptococcus.

Bacteriological methods. Throat swabs were streaked on 5% sheep blood agar plates and examined for beta-hemolytic colonies at 24 and 48 h. Strains were identified as group A or non-group A by the bactracin disk method of Maxted (13) and confirmed by the Lancefield grouping method (8) in the laboratory of Lewis W. Wannamaker. M typing by the

¹ Present address: University of Utah Medical Center, Salt Lake City, Utah 84132.
² Present address: Madison General Hospital, Madison, Wisc. 43715.
³ Present address: Los Angeles Childrens Hospital, Los Angeles, Calif. 90054.
capillary precipitin technique (18) and T agglutination reactions by the Griffith slide agglutination technique (14) were performed on selected isolates.

Administration and dosage. Patients received either cephalxin or one of the penicillins, phenoxy-
methyl or benzathine penicillin. The oral agents cep-
halxin and phenoxy-methyl penicillin were adminis-
tered for 10 days. The dosage of cephalxin was re-
lated to the available clinical capsular dose form of
the antibiotic. The dosage of the penicillins was ad-
justed by the weight category of the patient.

Cephalxin was administered four times daily to 66
patients, with 59 (89%) receiving doses of 250 mg;
three receiving 500 mg; three receiving 187 mg; and
one receiving 125 mg. A cephalxin oral suspension
was used in the four patients under 5 years of age, who
received 187 and 125 mg. Thirty-eight patients re-
ceived phenoxy-methyl penicillin: 250-mg doses were
administered to 18 patients three times daily and to
d12 four times daily; 125 mg was given to six patients
three times daily, and to two four times daily. Thirty
patients received an intramuscular injection of benza-
thane penicillin administered as 600,000 U if under 60
pounds (about 27 kg) or 1.2-ml U if over 60 pounds.

Antibiotic therapy was instituted immediately
after pharyngeal swabbing when patients manifested
pronounced symptoms. In most patients, however,
therapy commenced after bacteriological confirma-
tion. An instruction and information form explaining
the need for treating streptococcal pharyngitis was
given to the parents of each patient, and the impor-
tance of a 10-day course of therapy was stressed.

Blood was drawn for antistreptolysin O (ASO) deter-
mination at the time of initiation of therapy. For
follow-up: a second throat culture was obtained 3 to 5
days after the beginning of therapy, a third culture
was obtained 4 to 6 days after completion of therapy,
and another culture was obtained 21 to 28 days after
therapy ended. On return visits, physical examination
and urinalysis were performed and blood was drawn
for ASO determination. Therapy was considered suc-
cessful if the 4- to 6-day post-therapy culture was
negative for the original organism, i.e., beta-
hemolytic streptococci had been eliminated from the
pharynx.

ASO titer. ASO determinations were performed
according to the protocol of Edwards (3). After blood
was drawn and centrifuged, serum was removed and
stored in a frozen state at −15 C. All serum specimens
of a given patient were run at the same time. In
determining which titers were abnormally elevated,
the upper limits of normal were those established by
Klein et al. (7). Upper limits of normal for ASO titers
in the different age groups were defined as the level of
antibody titer exceeded by no more than 15% of the
subjects in that age group. These upper limits were 85
Todd units in children less than 1 year of age, 60 units
(1 to 4 years), 170 units (5 to 8 years), 120 units (9 to
12 years), 170 units (13 to 15 years), and 85 units in
adults. A 0.2-log or greater increment in titer was
considered a significant rise.

Antibiotic susceptibility testing. Data on mini-
mal inhibitory concentration (MIC) was obtained on
47 isolates from the cephalxin treatment group.

Susceptibility was determined by agar dilution tech-
nique (11, 12).

RESULTS

Patient population. Beta-hemolytic strepto-
cocci were recovered from the throats of 152
patients, the initial study population, of whom
128 were confined in the study until the end.
Twenty-three of the 24 were dropped because
they did not complete an appropriate course of
therapy or because of failure to obtain appropri-
ate follow-up cultures. Eight cephalxin-treated
patients and five phenoxy-methyl penicillin-
treated patients failed to provide end of treat-
ment (14-day) cultures and had admitted dubi-
ous compliance histories. Four cephalxin-
treated patients failed to provide 3-week fol-
low-up cultures, as did four phenoxy-methyl
penicillin-treatment patients and two benza-
thane penicillin-treated patients. In addition,
one patient was withdrawn from the study
because of an adverse reaction to cephalxin
during treatment.

In the study group of 128, 63 were males and
65 were females. There were 112 school-age
patients 5 to 16 years old and 12 pre-schoolers
2 to 4 years old. Another four patients, over age
16, were included because they were seen con-
currently with a younger family member in the
study group. Sex and age information are shown
in Table 1.

Bacteriological findings. All but six of the
128 patients of the study population were found
to have group A Streptococcus; of the six
non-group A, three were group C and three were
group G. The number of non-group A isolates is
low because of the initial screening of cultures of
patients included in the study population. The
non-group A isolates were all eliminated from
the pharynx, and their inclusion here was not
to alter efficacy comparison results.

Table 1. Sex and age of patients

<table>
<thead>
<tr>
<th>Patient group</th>
<th>Cephalxin (no. of patients)</th>
<th>Phenoxy-methyl penicillin (no. of patients)</th>
<th>Benzathine penicillin (no. of patients)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preschool (&lt;5 years)</td>
<td>5</td>
<td>2</td>
<td>5</td>
</tr>
<tr>
<td>School age (5-16 years)</td>
<td>58</td>
<td>31</td>
<td>23</td>
</tr>
<tr>
<td>Adult (&gt;16 years)</td>
<td>3</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Female</td>
<td>33</td>
<td>20</td>
<td>12</td>
</tr>
<tr>
<td>Male</td>
<td>33</td>
<td>14</td>
<td>16</td>
</tr>
</tbody>
</table>
Four bacteriological failures were recorded, two in the cephalixin treatment group and one each in the phenoxyethyl and benzathine penicillin groups. All of the failures were school age children 10 years or older. The daily dose of antibiotic received by each of the four patients whose treatment failed was at or below the median for his respective treatment group, when computed as milligrams or units per kilogram.

The daily dose in the cephalixin treatment group, using doses equivalent to the available capsular dose amounts (250 and 500 mg), ranged from 13.7 mg/kg per day to 80.2 mg/kg per day, with the median being 35.8 mg/kg per day. For the failures, daily dose was 35.5 mg/kg per day and 24.6 mg/kg, per day respectively. In the phenoxyethyl penicillin group the dose amounts ranged from 12.7 to 59 mg/kg, with a median of 25.1 mg/kg, and the single treatment failure was associated with a dose of 19.4 mg/kg per day. The dosage range for benzathine penicillin was 13,968 to 61,395 U/kg, with a median of 31,415 U/kg. The one patient for whom benzathine penicillin treatment failed received a dose calculable as 14,699 U/kg, the next to the lowest ratio recorded in the benzathine treatment group.

Recurrences occurred in four patients, three in the phenoxyethyl penicillin treatment group and one in the benzathine penicillin treatment group. A "recurrence" refers to a positive culture 21 to 28 days after completion of therapy when a culture taken 4 to 6 days after the completion of therapy had been negative.

Toxicity. Adverse reactions were seen in four of the 66 patients receiving cephalixin treatment (6.7%). Only one of these patients (1.5%) had a reaction, angioneurotic edema, severe enough to cause discontinuance of treatment altogether. In another patient with onset of diarrhea 1 day after treatment started, withdrawal of the antibiotic for 1 day brought relief and thereafter the therapeutic regimen was resumed. The remaining two patients reported mild diarrhea.

Angioneurotic edema developed in a 15-year-old male, weighing 96 pounds (about 44 kg), after he received a single 250-mg dose of cephalixin. Laboratory studies showed an essentially similar eosinophil count of 5% pretherapy and 6% after administration of cephalixin. A Coombs test was negative. Mild diarrhea continued for 3 days in a 6-year-old male patient, weighing 35 pounds (about 16 kg), who was receiving 250 mg of cephalixin four times daily. The eosinophil count in this patient went from 0% pretherapy to 9% during therapy and was 10% at the time of post-therapy follow-up. Also in this patient, serum glutamic oxalacetic transaminase was elevated at 14 days. Pretherapy urinalysis showed 2+ acetone, but findings on serial urinalysis thereafter were unremarkable.

Urinalysis. Fifty-eight cephalxin-treated patients (88%) had urinalysis pretherapy and/or during therapy plus at least one post-treatment urinalysis result. In none was there a constellation of findings suggesting glomerulonephritis.

ASO. Three serial ASO responses were recorded for 86 patients with group A streptococcal pharyngitis in the three treatment regimens. Fifty-five of the 86 (64%) had a significant rise over pretherapy levels (Table 2). Fifty-two percent of those treated with cephalixin demonstrated a rise in titer as compared to 78 to 80% of those treated with phenoxyethyl and benzathine penicillin, respectively.

Approximately one-half (28 strains or 48%) of the strains typed during the period of the study on which complete ASO profiles were obtained were M type 5, T agglutination pattern 5/27/44. The ASO titer was either initially elevated with no subsequent rise (6) or demonstrated at least a 0.2-log titer rise (20) in every patient from whom this strain was isolated. The distribution of this M type 5, T agglutination pattern

<table>
<thead>
<tr>
<th>Treatment group</th>
<th>No. tested</th>
<th>With 2-tube or 0.2-log titer rise</th>
<th>With no significant titer rise</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Initial titer elevated</td>
<td>Initial titer not elevated</td>
</tr>
<tr>
<td></td>
<td></td>
<td>No.</td>
<td>%</td>
</tr>
<tr>
<td>Cephalixin</td>
<td>48</td>
<td>18</td>
<td>37</td>
</tr>
<tr>
<td>Phenoxyethyl penicillin</td>
<td>18</td>
<td>12</td>
<td>67</td>
</tr>
<tr>
<td>Benzathine penicillin</td>
<td>20</td>
<td>11</td>
<td>55</td>
</tr>
</tbody>
</table>
5/27/44 strain was equivalent in each treatment group. The remaining one-half (30) of strains isolated from patients on whom complete ASO profiles were obtained comprised 18 M- and T-type patterns alone. There were 19 of 31 (61%) of these in which an 0.2-log or greater ASO titer rise was demonstrated, with 11 of 15 (73%) showing rises in the benzathine and phenoxyethyl penicillin treatment groups and only 8 of 16 (50%) in the cephalexin treatment group.

MIC. In the cephalexin treatment group, isolates from 47 patients (44 group A, three group C) were susceptible to MICs of the antibiotic within the range 0.1 to 6.3 µg/ml. All but four isolates were susceptible to an MIC of 0.8 µg/ml or less, with two isolates of group A streptococci susceptible at each of the 1.6- and 6.3-µg levels. Susceptibility testing results are available on only one of the isolates from the two cephalexin treatment group failures. This organism was susceptible at the 0.4-µg level.

DISCUSSION
The therapeutic outcome in this study with cephalexin as given according to available capsular dosage amounts is consistent with results reported by other investigators. The dosage range on a per kilogram basis was considerable, but seemed not to play a role in the success of cephalexin as an antistreptococcal agent. Dosages as low as 13.7 mg/kg per day resulted in bacteriological cures without recurrence, indicating the considerable therapeutic potency of cephalexin against the group A Streptococcus. The high rate of elimination of streptococci with the oral agents used in this study is felt to be in part attributable to the close contact and supervision of the patients. The use of an information and explanation form, the easily visible dosage administration check list, the mid-therapy visit, and the realization of the impending follow-up visit all undoubtedly contributed to the high success rate. In a recent study, Shapera et al. (16), using a comparable approach to encourage compliance, found similar high success rates by using oral phenoxyethyl penicillin and erythromycin estolate. In that study urine samples were obtained for measurement of antibiotic presence to verify patient compliance.

In four therapeutic trials (1, 4, 10, 18) comparing cephalexin with other antistreptococcal agents (Table 3), the cure rate in cephalexin-treated patients, ranged from 90 to 96.7%. In an additional study of the therapeutic efficacy of cephalexin, Disney et al. (2) cite a lower cure rate of 80.9%, but they include as failures recurrences (12.4%) and carriers (5.6%) defined as those with a 5-week positive culture after negative cultures in the earlier convalescent period. Clearly, final determination of results at an earlier point in the post-therapy period would yield a higher figure, although Aximi et al. (1), who did periodic cultures until 5 weeks elapsed, found only two bacteriological relapses (0.8% incidence). Similarly, we found no recurrences with cephalixin-treated patients.

It should be stressed that the success rate with oral therapy in these studies can be misleading to the physician. Oral therapy in a study setting is reinforced by the enthusiasm and follow-up of the investigators. Compliance in most situations will not be as complete, especially if all of the measures used herein are not followed. Therefore, when possible, benzathine penicillin should be used and should be administered in the appropriate dosage. As was pointed out earlier, the single failure with benzathine penicillin occurred in a patient who received only 14,699 U/kg, the next to the lowest ratio recorded in that treatment group. A more appropriate dose may well have resulted in a cure.

The results of ASO titer rises obtained in this study are high compared to other results in our laboratory (16) and from other studies carried out here in Minnesota in the same patient population a few years earlier (5). However, approximately one-half of the strains recovered during this winter-months study were of a single epidemic strain with an M type 5 pattern not seen during the earlier study period (5) and which in this study was shown to be ubiquitously associated with either an already elevated ASO titer (25%) or with at least a 0.2-log titer rise (75% of these strains). This could also be interpreted to indicate that during this period of epidemic streptococcal pharyngitis a higher percentage of patients were truly infected with streptococcus and there were fewer carrier states included in the study population. These M type 5 strains were all from the same community and represented, in this study, an M type not found in this population previously (5), and not common in this area in the experience of the streptococcal research group at the University of Minnesota (E. L. Kaplan, personal communication). In addition, the patient population, i.e., county hospitals outpatients, may represent patients who were in high percentage activity infected at the time of being seen for treatment. Since most patients were not treated until bacteriological confirmation was obtained, the additional 2 to 3 days necessary to confirm the presence of group A orga-
TABLE 3. Efficacy of cephalexin in comparative studies

<table>
<thead>
<tr>
<th>Study (reference)</th>
<th>Cephalexin cure (%)</th>
<th>Phenoxymethyl cure (%)</th>
<th>Benzathine cure (%)</th>
<th>Other oral agents cure (%)</th>
<th>Regimen and criteria of cure (day 1 – 1st day of medication)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Present study</td>
<td>96.7 (66)</td>
<td>97.1 (34)</td>
<td>96.4 (28)</td>
<td>76.3 (58)*</td>
<td>Medication for 10 days, 250 mg four times daily (125 if patient was &lt;1 year old). Culture negative until 5 weeks</td>
</tr>
<tr>
<td>Azimi et al. (1)</td>
<td>92 (25)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Disney et al. (2)</td>
<td>80.9 (89)</td>
<td></td>
<td></td>
<td>100 (84)*</td>
<td>Medication for 10 days, 30-40 mg of cephalexin per kg daily, 25,000-50,000 U of penicillin G. Culture negative until 5 weeks</td>
</tr>
<tr>
<td>Gau et al. (4)</td>
<td>96 (25)</td>
<td>92 (25)</td>
<td></td>
<td></td>
<td>Same as above. Cephalexin-treated group on 5 days of medication</td>
</tr>
<tr>
<td>Gau et al. (4)</td>
<td>88 (25)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leiderman et al. (9)</td>
<td>94 (94)</td>
<td></td>
<td></td>
<td>73 (37)*</td>
<td>Medication for 10 days, 0.05 g daily. Negative culture after day 7 and at least one negative between days 18-31</td>
</tr>
<tr>
<td>Stillerman et al. (17)</td>
<td>90 (84)</td>
<td>78 (89)*</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Penicillin.  
* Cephaloglycin.  
* Ampicillin.  
* Integrates data from earlier study by same author.

nisms may have allowed an additional opportunity for antibody production.

The incidence of clinical side effects associated with cephalexin treatment in four of the studies cited in Table 3 was lower than the incidence (6.7%) for the present study. Azimi et al. (1) did not report any clinical side effects. Leiderman et al. (9) reported one instance of erythematous papular rash at 8 days, disappearing 2 days after withdrawal of therapy. Disney et al. (2) reported extensive maculopapular rash in two patients on day 9, persistent diarrhea in one patient, transient diarrhea in one patient, and urticaria of limited duration in one patient. Stillerman et al. (17) found mild diarrhea in three patients and petechial rash in one patient on days 11 to 13 after start of therapy. Gau et al. (4), who had a higher incidence of side effects reported than the other studies (14%), uniquely listed as side effects headache in five patients and vaginal discharge in two others.

In considering cephalexin as an alternative to benzathine penicillin in patients for whom a history of penicillin allergy is present, it is important to consider that approximately 5% of patients demonstrating true penicillin allergy will also have an adverse reaction to the cephalosporins. Similarly, as erythromycin is the historical alternative to penicillin for streptococcal pharyngitis in penicillin-sensitive patients, it is of note that the rate of erythromycin adverse reactions (7%) (16) is similar in our experience to that seen in this investigation with cephalexin, although in the erythromycin population (86 patients) there were three patients who developed rashes and three patients who developed gastrointestinal symptoms of sufficient severity to warrant using an alternative antibiotic.

Any discussion of cephalexin as an alternative to erythromycin in penicillin-allergic individuals must include the consideration of cost to the patient. At this time a course of therapy is more expensive with cephalexin.

The efficacy of cephalexin in the treatment of beta-hemolytic streptococcus in this study proved to be on a par with efficacy of oral and
intramuscular penicillin as measured by the elimination of group A streptococci from the pharynx. Although the percentage of bacteriological cures with benzathine penicillin was no greater than with either of the oral regimens, this route of administration remains the treatment of choice, especially when compliance with an oral regimen seems in doubt. Careful explanation of the importance of administering the full course of treatment, the use of an easily visible dosage administration checklist, and follow-up reminders during the treatment period appear to result in improved bacteriological cures, making the results of oral therapy approach those of parenteral therapy. The low incidence of side effects and the generally mild nature of side effects, as determined in this study and others surveyed, make cephalaxin appear to be an acceptable alternative to penicillin in treatment of streptococcal pharyngitis when an oral agent is desired.

ACKNOWLEDGMENTS
This investigation was supported in part by a grant from Eli Lilly and Co., in part under the Sponsorship of the Commission on Streptococcal and Staphylococcal Diseases, Armed Forces Epidemiological Board, and in part by the U.S. Army Medical Research and Development Command under contract no. DADA 17-70-C00181 (L. W. Wannamaker, principal investigator).

LITERATURE CITED